Shield Therapeutics plc

Pharmaceutical ManufacturingEngland, United Kingdom51-200 Employees

Shield Therapeutics plc is a mid-sized pharmaceutical company focused on iron deficiency treatments. Based in Gateshead, England, it develops and commercializes ACCRUFeR/FeRACCRU, ferric maltol, to address iron deficiency with or without anemia. The company operates as a commercial-stage specialty pharmaceutical business, distributing ACCRUFeR through a US launch under an exclusive, multi-year collaboration with Viatris, and licensing rights to five specialty firms outside the United States. In the UK and European Union, FeRACCRU is marketed by Norgine B.V., which also holds marketing rights in Australia and New Zealand, while other exclusive licenses cover China, Hong Kong, Macau and Taiwan with Beijing Aosaikang Pharmaceutical; Korea with Korea Pharma; Canada with Kye Pharmaceuticals; and Japan with MEDLEAP.

Its patient base includes individuals with iron deficiency, with or without anemia, and the healthcare providers who treat them. The company operates within the pharmaceutical manufacturing industry and builds its international reach through a network of regional partners and licensees. In January 2025, Shield appointed Anders Lundstrom as permanent chief executive officer, reflecting ongoing leadership transition as it expands its commercial footprint.

Sign up for free to view info

Email Format Employee directory